BERLIN, November 17 The German government's activesupport of biotechnology investments is one of the country's leadingadvantages to international investors. The German government's strategy offostering innovation in biotechnology and possible benefits of such supportto foreign companies will be the focus of a presentation series at Bio-Europe2008 on November 17, 2008 in Mannheim, Germany addressing opportunities forforeign biotech investors in Germany. The presentation series takes placeduring the Bio-Europe 2008 convention, running November 17-19, 2008 inMannheim.
Germany's support of biotechnology investments has helped turn thecountry into the home of 500 biotech companies and make it a leader inspecialist areas such as regenerative medicine. Public funding forbiotechnology in Germany will be the topic of Dr. Stefan Lampel'spresentation. He is the head of EU and International Affairs for the ProjectManagement Organization Juelich. His talk will also examine eligibilitycriteria for foreign companies to receive public funds.
Industry clusters have helped Germany become a leader in health care andbiotechnologies as they allow for companies of all sizes to pool resources.The director of Germany's top health care cluster will be one of the speakersat the seminar. Dr. Christian Tidona, Managing Director of BioRN ClusterManagement GmbH, will discuss how his cluster won a Euro 40 million researchgrant. With this grant, companies in the cluster hope to develop up to 70 newdrugs, diagnostics, and platform technologies, in addition to 19 innovativeservices by 2013. The BioRN Cluster is also the home of 2008 Nobel LaureateProfessor Dr. Harald zur Hausen.
Lastly, the presentation series will focus on regenerative medicine.Germany's expertise in this area allows for foreign companies to use thecountry as a base for R&D activities in this exciting area of medicalresearch. This will be the topic of Dr. Anja Elstner's presentation. She isthe network manager for the Regenerative Medicine Initiative at theBerlin-Brandenburg Center for Regenerative Therapies. She will discuss therole of the German Ministry of Education and Research (BMBF) and the GermanResearch Foundation in supporting specialized research centers focusing onregenerative medicine. These centers located in the German cities of Berlin,Leipzig, Dresden, and Hannover and will receive Euro 150 million in support.
Dr. Nicola Henneberg, Senior Manager for Healthcare at Invest in GermanyGmbH, will start the presentation series with an introduction to Germany as abiotech investment location. She notes, "Government support, along with anexcellent workforce, have helped make Germany one of the world's top playersin biotechnology and a leader in regenerative medicine. The presence ofclusters helps make the country particularly welcoming to small andmedium-sized enterprises as new entrants can plug into a pre-existinginfrastructure and then focus only on its core competence, such as R&D."
Invest in Germany is the inward investment promotion agency of theFederal Republic of Germany. It provides investors with comprehensive supportfrom site selection to the implementation of investment decisions.Media Contact: Eva Henkel Invest in Germany Phone: +49-30-200099-173 Fax: +49-30-200099-111 Email: Henkel@invest-in-germany.com
SOURCE Invest in Germany